NeurAxis drops terms in latest filing for proposed $15 million initial public offering (NRXS).

2D illustrations and photos

Medical device manufacturer NeurAxis (NASDAQ:NRXS) dropped the terms of its proposed $15 million IPO in the most recent filing.

The company’s most recent filing did not list any terms of the deal. In the company’s previous filing in February, NeurAxis said so was interested in offering 1.9 million units at $8 per unit. Each unit would have consisted of one share plus a warrant to purchase one share at a price of $8 per share.

The selling shareholders had planned to offer 1.1 million shares. According to the filing in February, NeurAxis would not have received any proceeds from this sale.

NeurAxis hopes to list its shares on the Nasdaq under the symbol NRXS. Alexander Capital acts as sole lead manager.

Indiana-based NeurAxis is working on neuromodulatory therapies for children suffering from chronic and debilitating diseases. Its lead product, IB-Stim, has been approved by the FDA as a non-implantable nerve stimulator for the treatment of functional abdominal pain associated with irritable bowel syndrome.

More on NeurAxis:

Medical device maker NeurAxis is proposing a unit price of $8 in a $15 million IPO

NeurAxis is targeting a $15 million IPO for device expansion

Medical device maker NeurAxis sets terms for $15 million IPO